Clinical Trial Update: Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating irinotecan in combination with docetaxel for refractory metastatic breast cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED